It has been the subject of a trial by the [[National Cancer Institute]] to determine its effects in young cancer patients (up to 25 years of age) for its ability to locate [[malignant]] cancer cells without harming normal cells.  Specific cancers being included in the trial include [[neuroblastoma]], childhood [[brain tumour]]s and [[gastrointestinal cancer]].<ref>[http://www.clinicaltrials.gov/ct/show/NCT00049023?order=65 Radiolabeled Octreotide in Treating Children With Advanced or Refractory Solid Tumors]</ref>
